Saudi Arabia’s Avalon Pharma sets eyes on global expansion

Saudi Arabia pharmaceutical giant Avalon Avalon Pharma has unveiled plans to continue its advancement with a multi-pronged international expansion plan.

With a target to boost total exports from 10 per cent to 30 per cent by 2030, the home-grown pharmaceutical firm said its ambitious expansion plan will leverage its 25-year history in Saudi Arabia by aiming at new international markets.

Avalon Pharma said it will continue to introduce its health and prescription medicine expertise across the GCC and beyond, driven by emphasis on innovation, research and development.

The company’s expansion strategy is to refocus efforts in these markets through partnerships with distributors specific to each market.

Avalon Pharma, which is being backed by the Saudi Export Development Authority (SEDA), has made considerable advancements by targeting its focused markets – the six countries of the GCC and Iraq.

SEDA is dedicated to making the global marketplace more available to Saudi companies by encouraging the use of Saudi products in international markets.​

“Our success in the pharmaceutical industry is based on more than two decades of success in Saudi Arabia, something we have built our expansion across the region on. Our goal is to increase total exports from 10 per cent to 30 per cent by 2030,” said Ahmad Al Tabbaa, chairman of the board at Avalon Pharma.

Al Tabbaa said Avalon Pharma’s growth strategy will be achieved by re-establishing its focus across key markets in the GCC, following the establishment of the company’s presence within Dubai Science Park, the region’s first science-focused business community.

The pharmaceutical firm also plans to open a regional office in Dubai staffed by a team dedicated to the company’s international growth strategy.

Avalon is currently distributing to more than 15 countries and its expansion plan will focus on strategic focus markets including Egypt, and emerging markets in East and West Africa.

Avalon Pharma’s global strategy

Avalon Pharma is best known for its wide-ranging products which include cosmeceuticals, oral hygiene products, sanitisers and herbal medicine. The company produces a broad portfolio of merchandise with plans to add increased stock to its portfolio.

The company’s partnership with the UAE’s largest pharmaceutical distributor City Pharmacy is expected to increase Avalon Pharma’s footprint across the Emirates.

“We are well-positioned to continue our expansion within the GCC and across several new markets. We have made numerous strides in the UAE which have furthered our growth aims,” said Mohamed Maher Al Ghannam, managing director & CEO of Avalon Pharma.

“We will also establish a country manager in Kuwait to help service Kuwait and Bahrain. Avalon Pharma has strengthened the global awareness of products ‘Made in Saudi’, offering new opportunities in the GCC and beyond.”

Further international expansion will take place by targeting emerging markets by championing the “Made in Saudi” tagline affixed to its products. Avalon Pharma closely with SEDA will be central to achieving these aims as the company continues to expand.

Read: Saudi Arabia’s PIF sets up Lifera to boost biopharma industry growth